Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395519 · ClinicalTrials.gov registry record · Phase 1
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by 858 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 12
- Study locations
NCT06395519: Recruiting Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by 858 Therapeutics.
NCT06395519 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by 858 Therapeutics. The registered enrollment target is 120 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06395519, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by 858 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Primary Outcome
Frequency of dose-limiting toxicities (DLTs), frequency and severity of AEs, including abnormal ECG parameters, and serious adverse events (SAEs)
Conditions Studied
Interventions
- DRUG ETX-19477
Study Locations (12)
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic - Phoenix
Connecticut
- Yale University, Yale Cancer Center - New Haven
Florida
- Mayo Clinic - Jacksonville
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06395519 shows while recruiting
NCT06395519 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ETX-19477 is the first listed.
NCT06395519 lists 12 locations in 11 states (New York, Arizona, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06395519 about?
NCT06395519 is a clinical study titled "A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies". This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
What is the current status of trial NCT06395519?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-05-13. Estimated completion is 2026-12.
What conditions does trial NCT06395519 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06395519?
The interventions under investigation include: ETX-19477 (DRUG).
Who is sponsoring clinical trial NCT06395519?
This trial is sponsored by 858 Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06395519 being conducted?
This trial has 12 study locations across Arizona, Connecticut, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06395519's enrollment target sits among peer trials
120 510th of 1224 higher than 703 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI